Discover 443 paid clinical trials in Tucson, Arizona. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
With major studies in this city focused on conditions like Alzheimer's disease, lymphoma, asthma, and various forms of cancer, Tucson offers participants access to innovative care and breakthrough treatments. The city’s strong research network provides opportunities for individuals seeking to explore new treatment options while making a positive impact on medical research and advancements in healthcare.
Filter
2
Filter results
Results: 443
CardioFocus HeartLight Post-Approval Study
for
Atrial Fibrillation
Location: Tucson AZ, Chicago IL, Charlottesville VA, New York NY
Sponsor: CardioFocus
Sex: All
Age: 18+
Code: NCT03168659
Recruiting
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
for
Refractory Angina
Location: Tucson AZ, Scottsdale AZ, Phoenix AZ, San Diego CA,
Sponsor: Shockwave Medical, Inc.
Sex: All
Age: 18+
Code: NCT05102019
Recruiting
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
for
Peripartum Cardiomyopathy, Postpartum
Location: Tucson AZ, La Jolla CA, Orange CA, Los Angeles CA,
Sponsor: Dennis M. McNamara, MD, MS
Sex: Female
Age: 18+
Code: NCT05180773
Recruiting
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
for
Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF),
Location: Tucson AZ, Imperial CA, Vista CA, Pasadena CA,
Sponsor: Cytokinetics
Sex: All
Age: 40 - 70+
Code: NCT06793371
Phase 2, Recruiting
Effectiveness of Transcranial Magnetic Stimulation of the Default Mode Network to Improve Sleep - Clinical Trial
for
Insomnia
Location: Tucson AZ
Sponsor: University of Arizona
Sex: All
Age: 18 - 60
Code: NCT06631209
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies